Table 3.
Results of HIV-1-DNA quantification and characterization in patient IciS-11.
| Time Point (Days) | Chimerism (%) | Ultrasensitive RNA Quantification (Copies/mL) | Patient Material | ddPCR (Copies/106 Cells) | Gp120V3-Sequence (Dominant FPR; Range, %) | |
|---|---|---|---|---|---|---|
| HIV-1 LTR | HIV-1 Pol | |||||
| Pre allo-HSCT | ||||||
| −22 | PBMCs | 279 | 21 | 18.0 (18.0–70.5) | ||
| −20 | BM | 73 | <14 | 70.5 (39.4–70.5) | ||
| −14 | 2 | Tn | 571 | 69 | 31.8 (18.0–70.5) | |
| Tscm | 490 | ND | 9.7 (9.7–50.3) | |||
| Tcm | 2222 | 544 | 42.4 (22.1–77.3) | |||
| Ttm | 2780 | 838 | 42.4 (18.0–70.5) | |||
| Tem | 4629 | 882 | 21.8 (18.0–39.4) | |||
| Post allo-HSCT | ||||||
| +5 | 0 | PBMCs | trace | <5 | ||
| +27 | 60 | 3 | PBMCs | 378 | ND | |
| +55 | 0 | 2 | PBMCs | 534 | 72 | 31.8 (31.8–70.5) |
| Post 2nd allo-HSCT (days post 1st allo-HSCT) | ||||||
| +11 (+82) | 0 | PBMCs | 8 | ND | ||
| +27 (+98) | 0 | PBMCs | <2 | <4 | ||
| +35 (+106) | 100 | 0 | PBMCs | <2 | ND | |
| Post-mortem biopsies (one biopsy from same site is separated in two parts; 1,2) | ||||||
| +37 (+108) | Liver, biopsy 1; 2 | 60; <7 | ND; trace | No amplification | ||
| Lung left, biopsy 1; 2 | 28; <4 | ND; <4 | No amplification | |||
| Lung right, biopsy 1; 2 | trace; <3 | ND; <3 | No amplification | |||
| Spleen, biopsy 1; 2 | 60; <6 | ND; <6 | No amplification | |||
| Brain, biopsy 1; 2 | <4; <14 | <4; <4 | No amplification | |||
| 38 | LN CD4+ cells | 10 | <4 | No amplification | ||
Allo-HSCT, allogeneic hematopoietic stem cell transplantation. BM, bone marrow. ddPCR, droplet digital PCR. FPR, false-positive-rate. LN, lymph node. LTR, long terminal repeat DNA sequence ND, not done. NTC, no template control. PBMCs, peripheral blood mononuclear cells. pol, DNA polymerase DNA sequence. Tcm, central memory T-cell. Tem, effector memory T-cell. Tn, naive T-cell. Tscm, stem memory T-cell. Ttm, transitional memory T-cell.